Filtros de búsqueda

Lista de obras de Vaishali Sanchorawala

A case of atypical light chain deposition disease--diagnosis and treatment

artículo científico publicado en 2007

A library of ATTR amyloidosis patient-specific induced pluripotent stem cells for disease modelling and in vitro testing of novel therapeutics

scientific article published on 21 July 2018

A new era of amyloidosis: the trends at a major US referral centre

artículo científico publicado en 2019

A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.

artículo científico publicado en 2017

A second course of high-dose melphalan and auto-SCT for the treatment of relapsed AL amyloidosis

artículo científico publicado en 2010

AL amyloidosis associated with B-cell lymphoproliferative disorders: frequency and treatment outcomes

artículo científico publicado en 2006

AL amyloidosis: who, what, when, why, and where.

artículo científico publicado en 2012

Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy

artículo científico publicado en 2001

Amyloid deposits in the bone marrow of patients with immunoglobulin light chain amyloidosis do not impact stem cell mobilization or engraftment.

artículo científico publicado en 2012

Amyloidomics comes of age

artículo científico publicado en 2012

An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis

artículo científico publicado en 2007

Association of acquired von Willebrand syndrome with AL amyloidosis

scientific article published on 01 May 2007

Azotemia associated with use of lenalidomide in plasma cell dyscrasias

artículo científico publicado en 2008

Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study

artículo científico publicado en 2011

Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects

article

Bortezomib ocular toxicities: Outcomes with ketotifen

article

Cardiac amyloidosis: evolving approach to diagnosis and management

scientific article published on 01 December 2011

Cardiac biomarkers and health-related quality of life in patients with light chain (AL) amyloidosis

scientific article published on 22 November 2018

Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure

artículo científico publicado en 2010

Challenges in the Management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic

artículo científico publicado en 2020

Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantation

artículo científico publicado en 2006

Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis

artículo científico publicado en 2020

Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures.

artículo científico publicado en 1994

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

artículo científico publicado en 2005

Delay treatment of AL amyloidosis at relapse until symptomatic: devil is in the details

artículo científico publicado en 2019

Development and validation of a survival staging system incorporating BNP in patients with light chain (AL) amyloidosis

article

Diaphragm paralysis in primary systemic amyloidosis.

artículo científico publicado en 2005

Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis

artículo científico publicado en 2010

Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease.

artículo científico publicado en 2001

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study

artículo científico publicado en 2011

Establishment of brain natriuretic peptide - based criteria for evaluating cardiac response to treatment in light chain (AL) amyloidosis

artículo científico publicado en 2019

Febrile reactions occurring with second cycle of high-dose melphalan and SCT in patients with AL amyloidosis: a 'melphalan recall' reaction

artículo científico publicado en 2009

Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation.

artículo científico publicado en 2017

Heparin-induced thrombocytopenia and thrombosis during high dose melphalan and autologous stem cell transplantation

artículo científico publicado en 2018

Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver disease.

artículo científico publicado en 2009

High Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to AL Amyloidosis and Monoclonal Immunoglobulin Deposition Disease.

artículo científico publicado en 2017

High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study

artículo científico publicado en 2004

High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease

artículo científico publicado en 2003

High-dose melphalan and autologous peripheral blood stem cell transplantation in patients with AL amyloidosis and cardiac defibrillators

scientific article published on 21 January 2019

High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center.

artículo científico publicado en 2012

High-dose melphalan and stem cell transplantation in AL amyloidosis with elevated cardiac biomarkers

artículo científico publicado en 2018

Immunologic recovery after autologous blood stem cell transplantation in patients with AL-amyloidosis

artículo científico publicado en 2001

Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation.

artículo científico publicado en 2004

Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis

artículo científico publicado en 2010

Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.

artículo científico publicado en 2015

Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis

scientific article published on 11 January 2019

Kidney dysfunction during lenalidomide treatment for AL amyloidosis.

artículo científico publicado en 2010

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial

artículo científico publicado en 2006

Localized amyloidosis of the breast: a case series

artículo científico publicado en 2011

Long term outcome of patients treated on clinical trials of immunomodulatory agents for the treatment of Immunoglobulin light chain (AL) amyloidosis: A pooled analysis

scientific article published on 03 May 2019

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience

artículo científico publicado en 2015

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation

artículo científico publicado en 2007

Long-term outcome of patients with monoclonal Ig deposition disease treated with high-dose melphalan and stem cell transplantation

artículo científico publicado en 2010

Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis.

artículo científico publicado en 2002

Macroglossia – not always AL amyloidosis

article

Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial

artículo científico publicado en 2012

Microbiologically documented infections in patients undergoing high-dose melphalan and autologous stem cell transplantation for the treatment of light chain amyloidosis.

artículo científico

Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis

artículo científico publicado en 2018

Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR).

artículo científico publicado en 2018

Multiple arterial and venous thromboembolic complications in AL amyloidosis and cardiac involvement: a case report and literature review.

artículo científico

Neuralgic amyotrophy following high-dose melphalan and autologous peripheral blood stem cell transplantation for AL amyloidosis

artículo científico publicado en 2017

New hematologic response criteria predict survival in patients with immunoglobulin light chain amyloidosis treated with high-dose melphalan and autologous stem-cell transplantation

artículo científico publicado en 2013

Once AL amyloidosis: not always AL amyloidosis

artículo científico publicado en 2018

Oral cyclic melphalan and dexamethasone for patients with AL amyloidosis.

artículo científico publicado en 2010

Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis

artículo científico publicado en 2020

Orthotopic heart transplant rejection in association with immunomodulatory therapy for AL amyloidosis: A case series and review of the literature

artículo científico publicado en 2019

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients

artículo científico publicado en 2011

Outcomes of patients with AL amyloidosis and low serum free light chain levels at diagnosis

scientific article published on 21 July 2018

Patient Outcomes in Light Chain (AL) amyloidosis: the Clock is Ticking from Symptoms to Diagnosis

scientific article published on 21 June 2020

Persistent pleural effusions in primary systemic amyloidosis: etiology and prognosis.

artículo científico publicado en 2003

Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial

artículo científico publicado en 2016

Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis.

artículo científico publicado en 2005

Predictive value of the new renal response criteria in AL amyloidosis treated with high dose melphalan and stem cell transplantation

artículo científico publicado en 2018

Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen

scientific article published on 19 June 2020

Prevalence and prognostic value of D-dimer elevation in patients with AL amyloidosis

scientific article published on 02 August 2019

Psychometric validation of the SF-36 Health Survey in light chain amyloidosis: results from community-based and clinic-based samples

artículo científico publicado en 2017

Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis

artículo científico publicado en 2005

Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities

artículo científico publicado en 2020

Regression of cardiac wall thickness following chemotherapy and stem cell transplantation for light chain (AL) amyloidosis

artículo científico publicado en 2011

Risk of second primary malignancy in patients with AL amyloidosis treated with lenalidomide

artículo científico publicado en 2013

Safety of autologous stem cell transplantation in patients with known Human T-cell Lymphotropic Viruses Type 1 and 2 infection: A case series of four patients

artículo científico publicado en 2019

Safety, Tolerability, and Response Rates of Daratumumab in Relapsed AL Amyloidosis: Results of a Phase II Study

scientific article published on 24 January 2020

Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis

artículo científico publicado en 2005

Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis.

artículo científico publicado en 2009

Spontaneous rupture of the spleen in AL amyloidosis.

artículo científico publicado en 2003

Systemic AL amyloidosis with an undetectable plasma cell dyscrasia: A zebra without stripes

scientific article published on 26 November 2019

Systemic immunoglobulin light chain amyloidosis

Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis.

artículo científico publicado en 2007

The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell Transplantation.

artículo científico publicado en 2016

The utility of repeat kidney biopsy in systemic immunoglobulin light chain amyloidosis

scientific article published on 09 October 2019

Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis

artículo científico publicado en 2003

Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives

scientific article published on 23 October 2019

Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosis.

artículo científico publicado en 2018

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda